Redx Pharma Takes Second Shot at Nasdaq Via Skye Merger

UK fibrosis biotech Redx Pharma has agreed to a reverse merger that would give it the Nasdaq listing of Skye, three years after its previous attempt at the same route was abandoned in 2023, according to Endpoints News.

Redx Pharma is going back to a door it could not get through the first time. The UK fibrosis specialist has agreed to a reverse merger that would hand it the Nasdaq listing of Skye, according to Endpoints News — three years after an earlier attempt at the same manoeuvre was axed in 2023.

For a company whose science sits in one of drug development's least forgiving fields, the logic is straightforward. Redx develops ROCK inhibitors — small molecules aimed at the Rho-associated kinase pathway, which sits behind the scarring and tissue stiffening that define fibrotic disease. That is a long, expensive research programme, and long, expensive research programmes need access to deep pools of capital. In practice, that means a US listing.

Why a reverse merger instead of an IPO

A reverse merger is the back entrance to a public market. Rather than filing for an initial public offering, pricing a book of new shares and hoping the window stays open long enough to get the deal away, a private company folds itself into an already-listed shell. The private company's shareholders end up owning the great majority of the combined entity, new management takes over, the name and ticker usually change, and the listing itself — the thing that took the shell company years and considerable expense to obtain — transfers intact.

The appeal is timing and certainty. An IPO can be pulled at the last minute by a bad tape; a reverse merger is a negotiated transaction between two boards. The trade-off is that the incoming company inherits whatever the shell brings with it: a share register full of holders who bought a different story, sometimes litigation, sometimes legacy programmes that have to be wound down or sold, and a market capitalisation that may bear little relation to what the private company thinks it is worth.

The route has been gaining traction across biotech. When public market appetite for new listings is uneven, dozens of small-cap developers whose lead assets have failed find themselves in an awkward position: the pipeline is worth little, but the cash on the balance sheet and the Nasdaq listing are worth something to somebody. Boards under pressure from shareholders to stop burning money on a dead programme have an obvious alternative to liquidation — merge with a private company that has science but no listing, and let holders keep a slice of the upside.

What Skye brings, and what happens to it

Skye's shares last changed hands at 0.50, down 7.30% on the session and near the bottom of a day range that ran from 0.47 to 0.88, based on the most recent close as of 20:00 GMT on 14 August 2026. The previous close was 0.54. That is a wide intraday band for a single session, and it is characteristic of how sub-dollar biotech shells trade when merger news reaches the market: thin volume, a headline that changes what the equity actually represents, and holders trying to work out whether they are being handed a stake in a new company or diluted out of relevance.

The two questions that matter for existing Skye holders are the ownership split and the treatment of what Skye already owns. In transactions of this shape, the split is typically driven by an agreed valuation for the private company set against the shell's net cash — meaning the amount of money in the bank after liabilities, not the headline market value. Legacy programmes are frequently spun out, licensed away or handed to former holders through a contingent value right, a contractual promise to pay out if a specific asset later generates money.

None of those terms are confirmed here, and investors should not assume them. What is confirmed is the direction of travel: Redx takes the listing.

The 2023 attempt hangs over this one

The first attempt failed. That is the single most important piece of context in this story, because it tells you two things. It tells you Redx's management has wanted a US listing for years and has been willing to pursue it through more than one counterparty. And it tells you the risk that hangs over every announced reverse merger — these deals are agreements, not completions. They require shareholder votes on both sides, they require the shell's cash position to hold up through closing, and they can be voted down or walked away from.

Shell shareholders sometimes conclude that a straight liquidation returns more per share than the equity stub they are being offered in a company whose assets are years from generating revenue. Private-side investors sometimes conclude that the shell's balance sheet has shrunk too much during negotiation to be worth the dilution. Either outcome ends the deal.

What to watch from here

The disclosures that will settle the investment case are the ones that come next: the pro forma ownership percentages, the combined cash runway and how many quarters of research it funds, whether Skye's existing pipeline stays in or leaves, whether any concurrent private placement accompanies closing, and the timetable to a shareholder vote. A financing struck alongside the merger is a common feature, and it is often the real determinant of whether the combined company has enough money to reach a meaningful data point.

The wider market backdrop was quiet on the day. The S&P 500 tracking fund closed at $776.34, down 0.20%; the Nasdaq 100 proxy finished at $731.07, off 0.14%; and the Dow 30 fund ended at $536.80, down 0.21%. Broad indices drifting sideways is not the environment that drives small-cap biotech financing — that is set by risk appetite for pre-revenue science, which moves on its own schedule.

For Redx, the prize is a permanent presence in the market where fibrosis programmes get funded. Fibrotic disease has drawn substantial pharmaceutical interest and repeated clinical disappointment, and a ROCK inhibitor developer with a Nasdaq ticker is better placed to raise against that opportunity than one without. Whether this attempt closes where the last one did not is the only question that counts.

Key facts

• Shell company share price: SKYE at 0.50, down 7.30%, most recent close as of 20:00 GMT, 14 Aug 2026
• Acquirer: Redx Pharma, UK fibrosis biotech and ROCK inhibitor developer
• Prior attempt: Redx's earlier reverse merger was axed in 2023
• Listing at stake: Skye's Nasdaq listing transfers to Redx if the deal closes

Frequently asked questions

What is Redx Pharma trying to do?

Redx Pharma, a UK biotech focused on fibrosis and developing ROCK inhibitors, has agreed a reverse merger that would give it the Nasdaq listing currently held by Skye. It is the company's second attempt at reaching a US public market by this route, after a previous reverse merger was abandoned in 2023.

How does a reverse merger work?

A private company folds itself into an already-listed company, usually one whose own pipeline has stalled. The private company's shareholders take majority ownership, its management takes control, and the listing transfers with the deal. It avoids the pricing risk of an IPO but means inheriting the shell's shareholder base and any legacy obligations.

Where did Skye shares last trade?

Skye last changed hands at 0.50, down 7.30% from a previous close of 0.54, as of the most recent close at 20:00 GMT on 14 August 2026. The session range was wide, running from 0.47 to 0.88 — typical volatility for a sub-dollar biotech share reacting to merger news.

What is a ROCK inhibitor?

ROCK inhibitors are small molecules that block Rho-associated kinase, an enzyme involved in the cell signalling that drives tissue scarring and stiffening. Because that process underlies fibrotic disease, the pathway has become a target for companies pursuing fibrosis treatments, an area with large potential and a long history of clinical setbacks.

What happens to Skye's existing pipeline and cash?

Those terms have not been disclosed in the announcement. In reverse mergers generally, the shell's net cash helps determine the ownership split, and legacy programmes are often spun out, licensed away, or passed to former shareholders via contingent value rights. Investors should wait for the pro forma disclosures before assuming any structure.

Why are biotech reverse mergers becoming more common?

When IPO conditions are uneven, small-cap developers whose lead drugs have failed are left holding valuable Nasdaq listings and cash but little pipeline. Merging with a private company that has science but no listing gives their shareholders a stake in something with upside, and gives the private company faster, more certain access to public capital.

Sources

• Redx tries again at reverse merger, with Skye this time, as route gains steam — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source